VITT is characterised by exposure to one of the aforementioned vaccines 4–30 days prior to presentation, followed by thrombosis, mild-to-severe thrombocytopenia, and a positive PF4-heparin enzyme-linked immunosorbent assay (ELISA). The gene discussed is PF4; the disease is deep vein thrombosis.